Therapeutic perspectives in bronchial vascular remodeling in COPD.

abstract：:As our understanding of the pathobiology and natural history of the various forms of interstitial lung disease (ILD) has evolved, so have our approaches to treating this heterogeneous group of lung disorders. The earliest pharmacologic agents used to treat various forms of ILD were corticosteroids, and corticosteroids...

journal_title：Therapeutic advances in respiratory disease

authors： Kim R,Meyer KC

更新日期：2008-10-01 00:00:00

abstract：OBJECTIVES:Pharmacologically mediated bronchodilation is important in the management of asthma, and is primarily achieved with β₂-agonists. Novel compounds should preferably have a longer duration of action and a better systemic side effect profile than established alternatives at comparable peak bronchodilation. This ...

journal_title：Therapeutic advances in respiratory disease

authors： Bjermer L,Rosenborg J,Bengtsson T,Lötvall J

更新日期：2013-10-01 00:00:00

abstract：BACKGROUND:Central airway obstruction (CAO) is a serious condition that affects patients with both benign and malignant diseases. Timely recognition of CAO is crucial for prompt intervention aimed at improving the symptoms and quality of life of these patients. The aim of this study is to evaluate the formal radiology ...

journal_title：Therapeutic advances in respiratory disease

authors： Harris K,Alraiyes AH,Attwood K,Modi K,Dhillon SS

更新日期：2016-04-01 00:00:00

abstract：RATIONALE:Symptom relief is a key treatment goal in patients with chronic obstructive pulmonary disease (COPD). However, there are limited data available on the response to bronchodilator therapy in patients at low risk of exacerbations with different levels of symptom severity. This study compared treatment responses ...

journal_title：Therapeutic advances in respiratory disease

authors： Vogelmeier CF,Kerwin EM,Bjermer LH,Tombs L,Jones PW,Boucot IH,Naya IP,Lipson DA,Compton C,Barnes N,Maltais F

更新日期：2020-01-01 00:00:00

abstract：:The use of biomarkers on pleural fluid (PF) specimens may assist the decision-making process and enhance clinical diagnostic pathways. Three paradigmatic examples are heart failure, tuberculosis and, particularly, malignancy. An elevated PF concentration of the amino-terminal fragment of probrain natriuretic peptide (...

journal_title：Therapeutic advances in respiratory disease

authors： Porcel JM

更新日期：2018-01-01 00:00:00

abstract：:Immunotherapy has significantly altered the treatment landscape for many cancers, including non-small cell lung cancer (NSCLC). Currently approved immuno-oncology agents for lung cancer are aimed at the reversal of immune checkpoints, programmed death protein-1 (PD-1) and programmed death ligand-1 (PD-L1). Although re...

journal_title：Therapeutic advances in respiratory disease

authors： Villanueva N,Bazhenova L

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Disease severity may change in the first week after acute respiratory distress syndrome (ARDS) onset. The aim of this study was to evaluate whether the reclassification of disease severity after 48 h (i.e. day 3) of ARDS onset could help in predicting mortality and determine factors associated with ARDS pers...

journal_title：Therapeutic advances in respiratory disease

authors： Chiu LC,Lin SW,Liu PH,Chuang LP,Chang CH,Hung CY,Li SH,Lee CS,Wu HP,Huang CC,Li HH,Kao KC,Hu HC

更新日期：2020-01-01 00:00:00

abstract：OBJECTIVE:To identify potential predictors for invasive and non-invasive mechanical ventilation in coronavirus disease 2019 (COVID-19) patients. METHODS:This study retrospectively analyzes data of 516 patients with confirmed COVID-19, who were categorized into three groups based on which mechanical ventilation method ...

journal_title：Therapeutic advances in respiratory disease

authors： Li W,Lin F,Dai M,Chen L,Han D,Cui Y,Pan P

更新日期：2020-01-01 00:00:00

abstract：:In recent years in the management of pulmonary arterial hypertension (PAH), endothelin receptor antagonists (ERAs) represent a well-established class of therapeutic agents with clear beneficial effects. Macitentan (Opsumit®), a dual ERA optimized for efficacy and safety, is the newest drug in the class. Macitentan pre...

journal_title：Therapeutic advances in respiratory disease

authors： Steriade A,Seferian A,Jaïs X,Savale L,Jutant EM,Parent F,Sitbon O,Humbert M,Simonneau G,Montani D

更新日期：2014-06-01 00:00:00

abstract：BACKGROUND:Bacterial pneumonia is a major cause of acute respiratory distress syndrome (ARDS) requiring extracorporeal membrane oxygenation (ECMO) support. However, it is unknown whether the type of pneumonia, community-acquired pneumonia (CAP) versus hospital-acquired pneumonia (HAP), should be considered when predict...

journal_title：Therapeutic advances in respiratory disease

authors： Park C,Na SJ,Chung CR,Cho YH,Suh GY,Jeon K

更新日期：2019-01-01 00:00:00

abstract：:Fluoroquinolones are commonly used to treat lung infections in patients with cystic fibrosis. These patients are susceptible to lung infection with common bacteria such as Staphylococcus aureus and Haemophilus influenzae, but are also prone to infection by opportunistic bacteria, including Pseudomonas aeruginosa. The ...

journal_title：Therapeutic advances in respiratory disease

authors： Hurley M,Smyth A

更新日期：2012-12-01 00:00:00

abstract：BACKGROUND:Pseudomonas aeruginosa (Pa) is the predominant pulmonary pathogen in patients with cystic fibrosis (CF). Tobramycin nebulization is used for the eradication of Pa infection. Nowadays, tobramycin dry powder inhalation (DPI) is available as well. This study reports the results of eradicating Pa with tobramycin...

journal_title：Therapeutic advances in respiratory disease

authors： Akkerman-Nijland AM,Yousofi M,Rottier BL,Van der Vaart H,Burgerhof JGM,Frijlink HW,Touw DJ,Koppelman GH,Akkerman OW

更新日期：2020-01-01 00:00:00

abstract：:Allergen-specific immunotherapy remains the most likely effective treatment modality for allergic disorders by targeting the underlying immune mechanisms and possibly causing modifications in the disease course, as well as treating the symptoms. Treatment and compliance experiences been gained over nearly a century in...

journal_title：Therapeutic advances in respiratory disease

authors： Ozdemir C

更新日期：2009-10-01 00:00:00

abstract：BACKGROUND:It is unclear whether microRNAs could be a potential diagnostic biomarker for asthma or not. The objective of this study is to figure out the diagnostic value of microRNAs in asthma. METHODS:Literature retrieval, screening of publications, specific data extraction, and quality evaluation were conducted acco...

journal_title：Therapeutic advances in respiratory disease

authors： Xu L,Yi M,Tan Y,Yi Z,Zhang Y

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:N-chlorotaurine (NCT), a long-lived oxidant produced by human leukocytes, can be synthesized chemically and used topically as a well-tolerated antiseptic to different body regions including sensitive ones. The aim of this study was to test the tolerability of inhaled 1% NCT in aqueous solution upon repeated ...

journal_title：Therapeutic advances in respiratory disease

authors： Arnitz R,Stein M,Bauer P,Lanthaler B,Jamnig H,Scholl-Bürgi S,Stempfl-Al-Jazrawi K,Ulmer H,Baumgartner B,Embacher S,Geisler S,Gostner JM,Müllinger B,Kälz B,Nagl M

更新日期：2018-01-01 00:00:00

abstract：:A major impediment in the development of novel drugs for chronic obstructive pulmonary disease (COPD) has been the scarcity of a well-validated, robust, and easily obtainable intermediate end point such as serum biomarkers. To date the best serum biomarkers in COPD have been non-speci"c pro-in"ammatory molecules synth...

journal_title：Therapeutic advances in respiratory disease

authors： Sin DD,Pahlavan PS,Man SF

更新日期：2008-04-01 00:00:00

abstract：:It is well established that smoking is the primary preventable cause of disease and death in the United States and that it is responsible for a wide range of negative health consequences, including but not limited to respiratory disease. According to the US Public Health Service, all patients attempting to quit smokin...

journal_title：Therapeutic advances in respiratory disease

authors： Hudmon KS,Corelli RL,Prokhorov AV

更新日期：2010-02-01 00:00:00

abstract：:To investigate whether dry powder inhalers (DPIs) function in a constrained situation, a literature analysis was performed to evaluate the use of DPIs compared with established therapies in the treatment of acute asthma and COPD, irrespective of rapid-acting beta(2)-agonist used. The external databases Medline, Embase...

journal_title：Therapeutic advances in respiratory disease

authors： Selroos O,Borgström L,Ingelf J

更新日期：2009-04-01 00:00:00

abstract：:There is evidence of aberrations in the vitamin D-endocrine system in subjects with respiratory diseases. Vitamin D deficiency is highly prevalent in patients with respiratory diseases, and patients who receive vitamin D have significantly larger improvements in inspiratory muscle strength and maximal oxygen uptake. S...

journal_title：Therapeutic advances in respiratory disease

authors： Luong KV,Nguyen LT

更新日期：2013-12-01 00:00:00

abstract：BACKGROUND:Autologous blood is a novel, high-efficacy sclerosant for treatment of malignant pleural effusion (MPE), similar to tetracycline. There has been no comparative data between autologous blood and a worldwide sclerosant like talc. We aimed to compare the effectiveness of autologous blood versus talc pleurodesis...

journal_title：Therapeutic advances in respiratory disease

authors： Keeratichananont W,Kaewdech A,Keeratichananont S

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease (ILD). Currently, two antifibrotic drugs are available for reducing forced vital capacity (FVC) decline in IPF. However, many pulmonologists wait before initiating treatment, especially when IPF patients have stable dise...

journal_title：Therapeutic advances in respiratory disease

authors： Aono Y,Nakamura Y,Kono M,Nakamura H,Yokomura K,Imokawa S,Toyoshima M,Yasui H,Hozumi H,Karayama M,Suzuki Y,Furuhashi K,Enomoto N,Fujisawa T,Inui N,Suda T

更新日期：2020-01-01 00:00:00

abstract：OBJECTIVE:The ultra-short course preseasonal allergy vaccine, containing the adjuvant monophosphoryl lipid A (MPL), is effective in treating allergic symptoms; however, the efficacy in controlling asthmatics symptoms has not been fully demonstrated. We aimed at evaluating whether the ultra-short preseasonal course of i...

journal_title：Therapeutic advances in respiratory disease

authors： Scichilone N,Scalici V,Arrigo R,Bellia V

更新日期：2013-08-01 00:00:00

abstract：:Maintenance pharmacological treatment for stable chronic obstructive pulmonary disease (COPD) is based on inhaled drugs, including long-acting muscarinic receptor antagonists (LAMA), long-acting β2-adrenoceptor agonists (LABA) and inhaled corticosteroids (ICS). Inhaled pharmacological treatment can improve patients' d...

journal_title：Therapeutic advances in respiratory disease

authors： Malerba M,Nardin M,Santini G,Mores N,Radaeli A,Montuschi P

更新日期：2018-01-01 00:00:00

abstract：OBJECTIVES:To describe the health-related quality of life (HRQL) in a cohort of COPD patients recruited in primary care and identify the variables of the patients and the treatment associated with impaired HRQL. METHOD:Multicenter, observational study of patients with COPD recruited in Primary Care centers. Data regar...

journal_title：Therapeutic advances in respiratory disease

authors： Miravitlles M,Molina J,Naberan K,Cots JM,Ros F,Llor C,EVOCA study.

更新日期：2007-12-01 00:00:00

abstract：BACKGROUND:Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is well known as a life-threatening condition during its clinical course. However, the clinical features and prognosis in AE of unclassifiable idiopathic interstitial pneumonia (AE-UCIIP) remain to be elucidated. The aim of this study was to clarif...

journal_title：Therapeutic advances in respiratory disease

authors： Enomoto N,Naoi H,Aono Y,Katsumata M,Horiike Y,Yasui H,Karayama M,Hozumi H,Suzuki Y,Furuhashi K,Fujisawa T,Inui N,Nakamura Y,Suda T

更新日期：2020-01-01 00:00:00

abstract：:Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto® or Stiolto® is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting muscarinic receptor antagonist tiotropium (TIO) and the long-acting β2-adrenocep...

journal_title：Therapeutic advances in respiratory disease

authors： Derom E,Brusselle GG,Joos GF

更新日期：2019-01-01 00:00:00

abstract：:Chronic obstructive pulmonary disease (COPD) is a chronic condition that negatively affects several patient-centered outcomes. Among these, exercise capacity, dyspnea, and quality of life are the most relevant. In this article, factors contributing to exercise limitation, increase in exercise-induced dyspnea, quality ...

journal_title：Therapeutic advances in respiratory disease

authors： de Blasio F,Polverino M

更新日期：2012-08-01 00:00:00

abstract：:Current guidelines for the management of chronic obstructive pulmonary disease (COPD) establish that bronchodilator medications are central to the symptomatic treatment of the disease. Regular treatment with long-acting bronchodilators is recommended as more effective and convenient than short-acting bronchodilators, ...

journal_title：Therapeutic advances in respiratory disease

authors： Brienza NS,Amor-Carro O,Ramos-Barbón D

更新日期：2011-02-01 00:00:00

abstract：UNLABELLED:Alpha-1-antitrypsin deficiency [AATD] is associated with variable development of emphysema and other features of chronic obstructive pulmonary disease [COPD]. Matrix metalloproteinases [MMPs] are believed to be important in the pathophysiology of COPD, and may therefore confer susceptibility to this phenotyp...

journal_title：Therapeutic advances in respiratory disease

authors： McAloon CJ,Wood AM,Gough SC,Stockley RA

更新日期：2009-02-01 00:00:00

abstract：:Increased inflammatory cytokines [such as tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6)] are observed in COVID-19 patients, especially in the severe group. The phenomenon of a cytokine storm may be the central inducer of apoptosis of alveolar epithelial cells, which leads to rapid progression in severe g...

journal_title：Therapeutic advances in respiratory disease

authors： Chen XY,Yan BX,Man XY

更新日期：2020-01-01 00:00:00